The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study

被引:41
作者
Aloysius, Mark M.
Zaitoun, Abed M.
Beckingham, Ian J.
Neal, Keith R.
Aithal, Guruprasad P.
Bessell, Eric M.
Lobo, Dileep N. [1 ]
机构
[1] Univ Nottingham Hosp, Wolfson Digest Dis Ctr, Div Gastrointestinal Surg, Queens Med Ctr, Nottingham NG7 2UH, England
[2] Univ Nottingham Hosp, Queens Med Ctr, Dept Pathol, Nottingham NG7 2UH, England
[3] Univ Nottingham Hosp, Queens Med Ctr, Dept Publ Hlth Med & Epidemiol, Nottingham NG7 2UH, England
[4] Univ Nottingham Hosp, Wolfson Digest Dis Ctr, Dept Hepatol, Queens Med Ctr, Nottingham NG7 2UH, England
[5] City Hosp Nottingham, Univ Nottingham Hosp, Dept Clin Oncol, Nottingham NG5 1PB, England
关键词
chemotherapy; colorectal liver metastases; complications; FOLFOX-4; hepatectomy; neoadjuvant; outcome; oxaliplatin; steatosis;
D O I
10.1007/s00428-007-0497-1
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
FOLFOX-4 (folinic acid/5-fluorouracil/oxaliplatin) chemotherapy is used to treat patients with colorectal liver metastases. We aimed to assess hepatic histopathological responses to neoadjuvant FOLFOX-4 chemotherapy in patients with colorectal liver metastases. We selected all patients (n=54) treated with FOLFOX-4 for colorectal liver metastases between June 2002 and June 2005. Only 25 underwent hepatectomy and formed the study group. Histological responses were assessed in the study group and a matched control group (n=25) that did not receive neoadjuvant chemotherapy. The median (IQR) body mass index in the study and control groups was 24 (22-26) and 24 (23-25) kg/m(2), respectively, (P=NS). Complete histological resolution of tumour occurred in six (24%) patients in the study group. Median residual tumour cellularity was less (35 vs 70%) and fibrosis greater (50 vs 5%) in patients in the study group when compared with controls (P<0.001). The liver surrounding the tumour was steatotic in 17 (68%) patients in the study group and five (20%) controls (P= 0.001).Hepatic sinusoidal dilatation was more pronounced in patients in the study group than in controls (P<0.001). The response to FOLFOX-4 was associated with tumour necrosis, fibrosis and inflammation. More than two thirds of patients undergoing hepatectomy after FOLFOX-4 had steatosis despite being non-obese.
引用
收藏
页码:943 / 948
页数:6
相关论文
共 15 条
[1]  
Adam R, 2004, ANN SURG, V240, P644, DOI 10.1097/01.sla.0000141198.92114.16
[2]  
Adam R, 2001, ANN SURG ONCOL, V8, P347
[3]   Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases [J].
Allen, PJ ;
Kemeny, N ;
Jarnagin, W ;
DeMatteo, R ;
Blumgart, L ;
Fong, Y .
JOURNAL OF GASTROINTESTINAL SURGERY, 2003, 7 (01) :109-115
[4]   Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases [J].
Aloia, Thomas ;
Sebagh, Mylene ;
Plasse, Marylene ;
Karam, Vincent ;
Levi, Francis ;
Giacchetti, Sylvie ;
Azoulay, Daniel ;
Bismuth, Henri ;
Castaing, Denis ;
Adam, Rene .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (31) :4983-4990
[5]   Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741 [J].
Delaunoit, T ;
Alberts, SR ;
Sargent, DJ ;
Green, E ;
Goldberg, RM ;
Krook, J ;
Fuchs, C ;
Ramanathan, RK ;
Williamson, SK ;
Morton, RF ;
Findlay, BP .
ANNALS OF ONCOLOGY, 2005, 16 (03) :425-429
[6]   Pathological features of rectal cancer after preoperative radiochemotherapy [J].
Dworak, O ;
Keilholz, L ;
Hoffmann, A .
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 1997, 12 (01) :19-23
[7]   Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases [J].
Fernandez, FG ;
Ritter, J ;
Goodwin, JW ;
Linehan, DC ;
Hawkins, WG ;
Strasberg, SM .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2005, 200 (06) :845-853
[8]   Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases [J].
Karoui, M ;
Penna, C ;
Amin-Hashem, M ;
Mitry, E ;
Benoist, S ;
Franc, B ;
Rougier, P ;
Nordlinger, BD .
ANNALS OF SURGERY, 2006, 243 (01) :1-7
[9]   Oxaliplatin - In operable colorectal cancer [J].
Keam, SJ ;
Dunn, CJ ;
Figgitt, DP .
DRUGS, 2005, 65 (01) :89-96
[10]   Impact of steatosis on perioperative outcome following hepatic resection [J].
Kooby, DA ;
Fong, Y ;
Suriawinata, A ;
Gonen, M ;
Allen, PJ ;
Klimstra, DS ;
DeMatteo, RP ;
D'Angelica, M ;
Blumgart, LH ;
Jarnagin, WR .
JOURNAL OF GASTROINTESTINAL SURGERY, 2003, 7 (08) :1034-1043